Innate Pharma S.A. (FR:IPH) has released an update.
Innate Pharma S.A. reports a reduction in total assets from €207,863 thousand in 2022 to €184,193 thousand in 2023, alongside a decrease in net income from a loss of €58,103 thousand in 2022 to a loss of €7,570 thousand in 2023. The company’s financial statements also show a drop in both current and non-current liabilities. Notably, the net financial income improved, posting a gain of €5,099 thousand for 2023 compared to a loss of €546 thousand the previous year.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
